The Food and Drug Administration this week approved two abbreviated new drug applications expected to alleviate shortages and help during the COVID-19 emergency.

Dexmedetomidine hydrochloride 0.9% sodium chloride injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, and sedation of non-intubated patients prior to and/or during surgical and other procedures.

Succinylcholine chloride injection USP 200 mg/10 mL is indicated for general anesthesia, and to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.

Related News Articles

Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…